Phytomedicine polypharmacology: Cancer therapy through modulating the tumor microenvironment and oxylipin dynamics

被引:45
作者
Apaya, Maria Karmella [1 ,2 ,3 ]
Chang, Meng-Ting [2 ]
Shyur, Lie-Fen [1 ,2 ,3 ,4 ]
机构
[1] Acad Sinica, Taiwan Int Grad Program, Mol & Biol Agr Sci Program, Taipei 115, Taiwan
[2] Acad Sinica, Agr Biotechnol Res Ctr, 128,Sec 2,Acad Rd, Taipei 115, Taiwan
[3] Natl Chung Hsing Univ, Grad Inst Biotechnol, Taichung 40227, Taiwan
[4] Taipei Med Univ, Grad Inst Pharmacognosy, Taipei, Taiwan
关键词
Phytomedicines; Polypharmacology; Tumor microenvironment; Lipid mediators; Oxylipin; TRADITIONAL CHINESE MEDICINE; CONJUGATED LINOLEIC-ACID; NETWORK PHARMACOLOGY; PROSTATE-CANCER; PHASE-I; ANTITUMOR-ACTIVITY; NATURAL-PRODUCTS; CELL-GROWTH; PROSTAGLANDIN E-2; DRUG DEVELOPMENT;
D O I
10.1016/j.pharmthera.2016.03.001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Integrative approaches in cancer therapy have recently been extended beyond the induction of cytotoxicity to controlling the tumor microenvironment and modulating inflammatory cascades and pathways such as lipid mediator biosynthesis and their dynamics. Profiling of important lipid messengers, such as oxylipins, produced as part of the physiological response to pharmacological stimuli, provides a unique opportunity to explore drug pharmacology and the possibilities for molecular management of cancer physiopathology. Whereas single targeted chemotherapeutic drugs commonly lack efficacy and invoke drug resistance and/or adverse effects in cancer patients, traditional herbal medicines are seen as bright prospects for treating complex diseases, such as cancers, in a systematic and holistic manner. Understanding the molecular mechanisms of traditional medicine and its bioactive chemical constituents may aid the modernization of herbal remedies and the discovery of novel phytoagents for cancer management. In this review, systems-based polypharmacology and studies to develop multi-target drugs or leads from phytomedicines and their derived natural products that may overcome the problems of current anti-cancer drugs, are proposed and summarized. (C) 2016 Elsevier Inc. All rights reserved.
引用
收藏
页码:58 / 68
页数:11
相关论文
共 196 条
[1]  
Adams JD, 2013, RSC DRUG DISCOV, V31, P1, DOI 10.1039/9781849737852-00001
[2]  
Agarwal R, 2006, ANTICANCER RES, V26, P4457
[3]   Inflammation and cancer: How hot is the link? [J].
Aggarwal, Bharat B. ;
Shishodia, Shishir ;
Sandur, Santosh K. ;
Pandey, Manoj K. ;
Sethi, Gautam .
BIOCHEMICAL PHARMACOLOGY, 2006, 72 (11) :1605-1621
[4]   Statins and breast cancer prognosis: evidence and opportunities [J].
Ahern, Thomas P. ;
Lash, Timothy L. ;
Damkier, Per ;
Christiansen, Peer M. ;
Cronin-Fenton, Deirdre P. .
LANCET ONCOLOGY, 2014, 15 (10) :E461-E468
[5]   The tumour microenvironment as a target for chemoprevention [J].
Albini, Adriana ;
Sporn, Michael B. .
NATURE REVIEWS CANCER, 2007, 7 (02) :139-147
[6]  
Alexanian A, 2012, CANCER GENOM PROTEOM, V9, P163
[7]   Garlic and onions: their effect on eicosanoid metabolism and its clinical relevance [J].
Ali, M ;
Thomson, M ;
Afzal, M .
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 2000, 62 (02) :55-73
[8]   Polypharmacology: Challenges and Opportunities in Drug Discovery [J].
Anighoro, Andrew ;
Bajorath, Juergen ;
Rastelli, Giulio .
JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (19) :7874-7887
[9]  
[Anonymous], 2011, EVID BASED COMPLEMEN
[10]  
Apaya M. K., 2015, MOL MED